Trial · NCT00986245
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient Preference | After 16 weeks or at last visit for early completion | Patient preference between once-daily and twice-daily regimen |
| Secondary | Unified Parkinson's Disease Rating Scale, Part 3 | 8 weeks for each arm or at last visit | Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion. UPDRS part 3 is motor scale for parkinson's disease. Range: 0\~108 Higher values represent more severe motor symptoms of parkinsonism. |
| Secondary | Hoehn and Yahr Stage | 8 weeks for each arm or at last visit | Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0\~5 Higher values represent more severe parkinsonism |
| Secondary | Overall Quality of Sleep | 8 weeks for each arm or at last visit | Sleep questionnaire 1 for "Overall quality of sleep" Visual analogue scale: 0\~10 Higher values represent worse overall sleep quality. |
| Secondary | Nocturnal Off-symptoms | 8 weeks for each arm or at last visit | Sleep questionnaire 2 for "Nocturnal off-symptoms" Visual analogue scale: 0\~10 Higher values represent worse nocturnal off-symptoms. |
| Secondary | Early Morning Off Symptoms | 8 weeks for each arm or at last visit | Sleep questionnaire 3 for "early morning off symptoms" Visual analogue scale: 0\~10 Higher values represent worse early morning off symptoms. |
| Secondary | Epworth Sleep Scale | 8 weeks in each arm or at last visit for early completion | Epworth sleep scale after 8 weeks in each arm or at last visit for early completion. Range: 0\~24 Higher values represent worse daytime-sleepiness. |
| Secondary | Compliance | 8 weeks for each arm or at last visit | Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication. |
| Secondary | Adverse Events | After 8 weeks in each arm or at last visit for early completion | Patients who have adverse events |
| Secondary | Patients Who Have Global Impression for Improvement | After 8 weeks in each arm or at last visit for early completion | Patients who have global impression for improvement for each dosing. |
| Secondary | Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation | After 8 weeks in each arm or at last visit for early completion | Patients who have global impression for improvement to duration of motor fluctuation |
| Secondary | Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation | After 8 weeks in each arm or at last visit for early completion | Patients who have global impression for improvement to severity of motor fluctuation compared |
| Secondary | Patients Who Have Global Impression for Improvement to Duration of Dyskinesia | After 8 weeks in each arm or at last visit for early completion | Patients who have global impression for improvement to duration of dyskinesia compared |
| Secondary | Patients Who Have Global Impression for Improvement to Severity of Dyskinesia | After 8 weeks in each arm or at last visit for early completion | Patients who have Global Impression for Improvement to Severity of Dyskinesia compared |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00986245/registered